-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-9643 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-9643 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-9643 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: PL-9643...
-
Product Insights
NewNet Present Value Model: Palatin Technologies Inc’s PL-9643
Empower your strategies with our Net Present Value Model: Palatin Technologies Inc's PL-9643 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Lymphoma Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi, Darzalex Faspro) is...
-
Innovation Ranking
Innovation Ranking – Palatin Technologies Inc
Palatin Technologies Inc (Palatin) is a biopharmaceutical company that develops receptor specific peptide therapeutics. The company’s medicines are based on molecules that control the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product includes Vyleesi, indicated for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin clinical pipeline includes melanocortin receptor programs such as PL-8177 MC1r Agonist (oral) for inflammatory bowel disease; PL9643 MCr Agonist for dry eye diseases; PL-8177 MC1r Agonist (systemic) for Covid-19...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Gefurulimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Gefurulimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewChoroidal Neovascularization – Drugs In Development, 2024
Empower your strategies with our Choroidal Neovascularization – Drugs In Development, 2024 report and make more profitable business decisions. Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid, the pigmented vascular layer of tissue behind the retina. Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes anti-vascular endothelial growth factor (anti-VEGF) agents, laser photocoagulation, and photodynamic therapy. The Choroidal Neovascularization drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewFemale Sexual Dysfunction – Drugs In Development, 2024
Empower your strategies with our Female Sexual Dysfunction – Drugs In Development, 2024 report and make more profitable business decisions. Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen...
-
Product Insights
NewErectile Dysfunction – Drugs In Development, 2024
Empower your strategies with our Erectile Dysfunction – Drugs In Development, 2024 report and make more profitable business decisions. Erectile dysfunction (ED) is the inability of a man to have an erection hard enough to have sexual intercourse. It is also known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use, and medications including antidepressants, antihistamines, and medications to treat high blood pressure, pain, or prostate cancer. The Erectile Dysfunction drugs in development market research report...
-
Product Insights
NewRetinopathy – Drugs In Development, 2024
Empower your strategies with our Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of a systemic disease such as diabetes or hypertension. The Retinopathy...